胰腺癌新辅助治疗应用增加且最优结局改善
基于美国外科医师学会NSQIP胰腺切除专项数据库2014至2019年数据,共纳入13,257例因胰腺导管腺癌行胰十二指肠切除术的患者。新辅助治疗使用率从2014年的24.2%上升至2019年的42.7%(p < 0.0001),多变量分析显示新辅助治疗与严重并发症、临床相关胰瘘、器官腔隙感染、经皮引流、再手术及延长住院时间减少相关,且最优胰腺手术(OPS)达成率更高(OR 1.433,p < 0.001)。
要点
- 2014至2019年因PDAC行胰十二指肠切除术患者中新辅助治疗使用率由24.2%升至42.7%。
- 新辅助治疗与严重并发症(OR 0.83)、临床相关胰瘘(OR 0.52)等术后不良结局减少相关。
- 新辅助治疗患者OPS达成率更高(OR 1.433),且该比例随时间从50.7%升至56.6%。
核心结论
- 过去十年胰十二指肠切除术前新辅助治疗使用增加超过3倍,并与最优手术结局改善相关。
研究设计与样本
- 查询美国外科医师学会NSQIP胰腺切除专项数据库2014至2019年数据,纳入因PDAC行胰十二指肠切除术的患者,比较新辅助治疗与直接手术,采用多变量分析及Mann-Kendall趋势检验。
主要发现
- 共识别13,257例因PDAC行胰十二指肠切除术的患者,总体33.6%接受新辅助治疗。
- 新辅助治疗使用率从2014年的24.2%上升至2019年的42.7%(p < 0.0001)。
- 多变量分析显示新辅助治疗与严重并发症减少相关(OR 0.83,p < 0.001)。
- 新辅助治疗与临床相关胰瘘(OR 0.52,p < 0.001)、器官腔隙感染(OR 0.74,p < 0.001)、经皮引流(OR 0.73,p < 0.001)、再手术(OR 0.76,p = 0.005)及延长住院时间(OR 0.63,p < 0.001)减少相关。
- 新辅助治疗患者OPS达成更频繁(OR 1.433,p < 0.001),且接受新辅助治疗者OPS比例随时间从50.7%升至56.6%(p < 0.001)。
临床怎么用
- 因PDAC行胰十二指肠切除术的患者中,新辅助治疗的使用比例在2014至2019年间持续增加。
- 新辅助治疗与严重并发症、临床相关胰瘘、器官腔隙感染、经皮引流、再手术及延长住院时间减少相关。
- 新辅助治疗与OPS达成率更高相关,且该比例随时间改善。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of more effective chemotherapy a decade ago has led to increased use of neoadjuvant therapy (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to assess the evolving use of NAT in individuals with PDAC undergoing pancreatoduodenectomy (PD) and to compare their outcomes with patients undergoing upfront operation. STUDY DESIGN: The American College of Surgeons NSQIP Procedure Targeted Pancreatectomy database was queried from 2014 to 2019. Patients undergoing pancreatoduodenectomy were evaluated based on the use of NAT versus upfront operation. Multivariable analysis was performed to determine the effect of NAT on postoperative outcomes, including the composite measure optimal pancreatic surgery (OPS). Mann-Kendall trend tests were performed to assess the use of NAT and associated outcomes over time. RESULTS: A total of 13,257 patients were identified who underwent PD for PDAC between 2014 and 2019. Overall, 33.6% of patients received NAT. The use of NAT increased steadily from 24.2% in 2014 to 42.7% in 2019 (p < 0.0001). On multivariable analysis, NAT was associated with reduced serious morbidity (odds ratio [OR] 0.83, p < 0.001), clinically relevant pancreatic fistulas (OR 0.52, p < 0.001), organ space infections (OR 0.74, p < 0.001), percutaneous drainage (OR 0.73, p < 0.001), reoperation (OR 0.76, p = 0.005), and prolonged length of stay (OR 0.63, p < 0.001). OPS was achieved more frequently in patients undergoing NAT (OR 1.433, p < 0.001) and improved over time in patients receiving NAT (50.7% to 56.6%, p < 0.001). CONCLUSION: NAT before pancreatoduodenectomy increased more than 3-fold over the past decade and was associated with improved optimal operative outcomes.
引用
- Davis CH, Beane JD, Gazivoda VP, et al. Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes. J Am Coll Surg. 2022. PMID: 35290262. doi:10.1097/XCS.0000000000000095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。